Berg, D., M. Gerlach, M. B. Youdim, K. L. Double, L. Zecca, P. Riederer and G. Becker (2001). "Brain iron pathways and their relevance to Parkinson's disease." J Neurochem 79(2): 225-236.
Bobek, L. A. and M. J. Levine (1992). "Cystatins--inhibitors of cysteine proteinases." Crit Rev Oral Biol Med 3(4): 307-332.
Carlson, A. P., M. Abbas, R. L. Alunday, F. Qeadan and C. W. Shuttleworth (2018). "Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial." J Neurosurg: 1-7.
Crecelius, A., A. Gotz, T. Arzberger, T. Frohlich, G. J. Arnold, I. Ferrer and H. A. Kretzschmar (2008). "Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE." Proteomics 8(6): 1276-1291.
Deng, A., M. C. Irizarry, R. M. Nitsch, J. H. Growdon and G. W. Rebeck (2001). "Elevation of cystatin C in susceptible neurons in Alzheimer's disease." Am J Pathol 159(3): 1061-1068.
Dor, M., S. Eperon, P. H. Lalive, Y. Guex-Crosier, M. Hamedani, C. Salvisberg and N. Turck (2019). "Investigation of the global protein content from healthy human tears." Exp Eye Res 179: 64-74.
Drucker, G., K. Raikoff, E. J. Neafsey and M. A. Collins (1990). "Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products." Brain Res 509(1): 125-133.
Dumitriu, A., J. Golji, A. T. Labadorf, B. Gao, T. G. Beach, R. H. Myers, K. A. Longo and J. C. Latourelle (2016). "Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease." BMC Med Genomics 9: 5.
Espina, V., M. Heiby, M. Pierobon and L. A. Liotta (2007). "Laser capture microdissection technology." Expert Rev Mol Diagn 7(5): 647-657.
Galter, D., S. Buervenich, A. Carmine, M. Anvret and L. Olson (2003). "ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia." Neurobiol Dis 14(3): 637-647.
Gaudet, P., P. A. Michel, M. Zahn-Zabal, A. Britan, I. Cusin, M. Domagalski, P. D. Duek, A. Gateau, A. Gleizes, V. Hinard, V. Rech de Laval, J. Lin, F. Nikitin, M. Schaeffer, D. Teixeira, L. Lane and A. Bairoch (2017). "The neXtProt knowledgebase on human proteins: 2017 update." Nucleic Acids Res 45(D1): D177-D182.
Gearhart, D. A., E. J. Neafsey and M. A. Collins (2002). "Phenylethanolamine N-methyltransferase has beta-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson's disease." Neurochem Int 40(7): 611-620.
Greenbaum, D., C. Colangelo, K. Williams and M. Gerstein (2003). "Comparing protein abundance and mRNA expression levels on a genomic scale." Genome Biol 4(9): 117.
Grunblatt, E., S. Mandel, J. Jacob-Hirsch, S. Zeligson, N. Amariglo, G. Rechavi, J. Li, R. Ravid, W. Roggendorf, P. Riederer and M. B. Youdim (2004). "Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes." J Neural Transm (Vienna) 111(12): 1543-1573.
Hasegawa, A., M. Naruse, S. Hitoshi, Y. Iwasaki, H. Takebayashi and K. Ikenaka (2007). "Regulation of glial development by cystatin C." J Neurochem 100(1): 12-22.
Jenner, P. (2003). "Oxidative stress in Parkinson's disease." Ann Neurol 53 Suppl 3: S26-36; discussion S36-28.
Kalia, L. V. and A. E. Lang (2015). "Parkinson's disease." Lancet 386(9996): 896-912.
Kaur, G., P. Mohan, M. Pawlik, S. DeRosa, J. Fajiculay, S. Che, A. Grubb, S. D. Ginsberg, R. A. Nixon and E. Levy (2010). "Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy." Am J Pathol 177(5): 2256-2267.
Kopp, N., L. Denoroy, B. Renaud, J. F. Pujol, A. Tabib and M. Tommasi (1979). "Distribution of adrenaline-synthesizing enzyme activity in the human brain." J Neurol Sci 41(3): 397-409.
Kumada, T., A. Hasegawa, Y. Iwasaki, H. Baba and K. Ikenaka (2004). "Isolation of cystatin C via functional cloning of astrocyte differentiation factors." Dev Neurosci 26(1): 68-76.
Levitt, P., J. E. Pintar and X. O. Breakefield (1982). "Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons." Proc Natl Acad Sci U S A 79(20): 6385-6389.
Li, J. Z., M. P. Vawter, D. M. Walsh, H. Tomita, S. J. Evans, P. V. Choudary, J. F. Lopez, A. Avelar, V. Shokoohi, T. Chung, O. Mesarwi, E. G. Jones, S. J. Watson, H. Akil, W. E. Bunney, Jr. and R. M. Myers (2004). "Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions." Hum Mol Genet 13(6): 609-616.
Licker, V., N. Turck, E. Kovari, K. Burkhardt, M. Cote, M. Surini-Demiri, J. A. Lobrinus, J. C. Sanchez and P. R. Burkhard (2014). "Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis." Proteomics 14(6): 784-794.
Matsubara, K., T. Gonda, H. Sawada, T. Uezono, Y. Kobayashi, T. Kawamura, K. Ohtaki, K. Kimura and A. Akaike (1998). "Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease." J Neurochem 70(2): 727-735.
McGeer, P. L. and E. G. McGeer (2004). "Inflammation and neurodegeneration in Parkinson's disease." Parkinsonism Relat Disord 10 Suppl 1: S3-7.
McNaught, K. S., C. W. Olanow, B. Halliwell, O. Isacson and P. Jenner (2001). "Failure of the ubiquitin-proteasome system in Parkinson's disease." Nat Rev Neurosci 2(8): 589-594.
Michael, G. J., S. Esmailzadeh, L. B. Moran, L. Christian, R. K. Pearce and M. B. Graeber (2011). "Up-regulation of metallothionein gene expression in parkinsonian astrocytes." Neurogenetics 12(4): 295-305.
Miklya, I. (2016). "The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)." Mol Psychiatry 21(11): 1499-1503.
Moran, L. B., D. C. Duke, M. Deprez, D. T. Dexter, R. K. Pearce and M. B. Graeber (2006). "Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease." Neurogenetics 7(1): 1-11.
Plum, S., S. Steinbach, J. Attems, S. Keers, P. Riederer, M. Gerlach, C. May and K. Marcus (2016). "Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection." Sci Rep 6: 37139.
Redensek, S., V. Dolzan and T. Kunej (2018). "From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms." OMICS 22(1): 1-16.
Scherl, A., S. A. Shaffer, G. K. Taylor, H. D. Kulasekara, S. I. Miller and D. R. Goodlett (2008). "Genome-specific gas-phase fractionation strategy for improved shotgun proteomic profiling of proteotypic peptides." Anal Chem 80(4): 1182-1191.
Shimoji, M., F. Pagan, E. B. Healton and I. Mocchetti (2009). "CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease." Neurotox Res 16(3): 318-328.
Simunovic, F., M. Yi, Y. Wang, L. Macey, L. T. Brown, A. M. Krichevsky, S. L. Andersen, R. M. Stephens, F. M. Benes and K. C. Sonntag (2009). "Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology." Brain 132(Pt 7): 1795-1809.
Tizon, B., S. Sahoo, H. Yu, S. Gauthier, A. R. Kumar, P. Mohan, M. Figliola, M. Pawlik, A. Grubb, Y. Uchiyama, U. Bandyopadhyay, A. M. Cuervo, R. A. Nixon and E. Levy (2010). "Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines." PLoS One 5(3): e9819.
Tong, J., G. Rathitharan, J. H. Meyer, Y. Furukawa, L. C. Ang, I. Boileau, M. Guttman, O. Hornykiewicz and S. J. Kish (2017). "Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders." Brain 140(9): 2460-2474.
Vono, M., C. S. Eberhardt, F. Auderset, B. Mastelic-Gavillet, S. Lemeille, D. Christensen, P. Andersen, P. H. Lambert and C. A. Siegrist (2019). "Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers." Cell Rep 28(7): 1773-1784 e1775.
Xu, L., J. Sheng, Z. Tang, X. Wu, Y. Yu, H. Guo, Y. Shen, C. Zhou, L. Paraoan and J. Zhou (2005). "Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies." Neurobiol Dis 18(1): 152-165.
Yamamoto-Watanabe, Y., M. Watanabe, M. Jackson, H. Akimoto, K. Sugimoto, M. Yasujima, Y. Wakasaya, E. Matsubara, T. Kawarabayashi, Y. Harigaya, A. R. Lyndon and M. Shoji (2010). "Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3." Brain Res 1361: 140-145.
Zaccaria, A., A. Bouamrani, S. Chabardes, M. El Atifi, E. Seigneuret, J. A. Lobrinus, M. Dubois-Dauphin, F. Berger and P. R. Burkhard (2016). "Deep brain stimulation-associated brain tissue imprints: a new in vivo approach to biological research in human Parkinson's disease." Mol Neurodegener 11: 12.
Zucca, F. A., R. Vanna, F. A. Cupaioli, C. Bellei, A. De Palma, D. Di Silvestre, P. Mauri, S. Grassi, A. Prinetti, L. Casella, D. Sulzer and L. Zecca (2018). "Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease." NPJ Parkinsons Dis 4: 17.